Peer Review reports
From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
| Original Submission | ||
|---|---|---|
| 28 Feb 2018 | Submitted | Original manuscript |
| 14 Apr 2018 | Reviewed | Reviewer Report - Randolph Evans |
| 19 Apr 2018 | Reviewed | Reviewer Report - Hans-Christoph Diener |
| 24 Apr 2018 | Reviewed | Reviewer Report - Pierangelo Geppetti |
| 23 May 2018 | Author responded | Author comments - Angelo Camporeale |
| Resubmission - Version 2 | ||
| 23 May 2018 | Submitted | Manuscript version 2 |
| 12 Jun 2018 | Reviewed | Reviewer Report - Hans-Christoph Diener |
| 10 Sep 2018 | Author responded | Author comments - Angelo Camporeale |
| Resubmission - Version 3 | ||
| 10 Sep 2018 | Submitted | Manuscript version 3 |
| 26 Oct 2018 | Author responded | Author comments - Angelo Camporeale |
| Resubmission - Version 4 | ||
| 26 Oct 2018 | Submitted | Manuscript version 4 |
| Publishing | ||
| 31 Oct 2018 | Editorially accepted | |
| 9 Nov 2018 | Article published | 10.1186/s12883-018-1193-2 |
You can find further information about peer review here.